Supernus Pharmaceuticals (SUPN) Interest Expenses (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Interest Expenses data on file, last reported at $4.1 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 5.29% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $16.1 million, a 0.18% change from a year earlier, with the FY2025 full-year figure at $590.2 million, up 784.56% from the prior year.
• Interest Expenses for Q1 2026 stood at $4.1 million, up from $4.1 million in the prior quarter.
• Over the last five years, Interest Expenses for SUPN reached as high as $75.0 million in Q1 2022 and fell as low as $46000.0 in Q3 2025.
• Historically, Interest Expenses has averaged $11.6 million across 5 years, with a median of $3.9 million in 2024.
• Across the five-year window, Interest Expenses jumped 1270.04% in 2022 and tumbled 98.79% in 2023, its largest moves.
• Year by year, Interest Expenses stood at $1.6 million in 2022, then tumbled by 70.58% to $469000.0 in 2023, then soared by 765.46% to $4.1 million in 2024, then climbed by 0.25% to $4.1 million in 2025, then rose by 0.71% to $4.1 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $4.1 million in Q1 2026, $4.1 million in Q4 2025, and $46000.0 in Q3 2025.